Monopar Therapeutics Form 4 insider transactions

Monopar Therapeutics Chief Financial Officer, Quan Anh Vu, has acquired shares through the vesting and settlement of restricted stock units, with a portion withheld for taxes.

Chandler Robinson, CEO and Director of Monopar Therapeutics, reported transactions involving restricted stock units and common stock.

Monopar Therapeutics reports that Chief Operating Officer Andrew Cittadine acquired shares through the vesting and settlement of restricted stock units.

Monopar Therapeutics Director Nicole Sweeny acquired 1,284 stock options with an exercise price of $87.68, vesting in two tranches.

CEO Chandler Robinson acquired 6,732 shares of Monopar Therapeutics common stock through the vesting of restricted stock units.

Monopar Therapeutics Chief Operating Officer Andrew Cittadine acquired 3,514 shares via RSU vesting and withheld 1,571 shares for taxes.

Monopar Therapeutics' Chief Commercial and Strategy Officer, Susan Rodriguez, was granted 48,728 stock options with an exercise price of $53.47, vesting over four years.

Monopar Therapeutics CEO Chandler Robinson reported the indirect acquisition of 62,815 common shares through a pro rata liquidating distribution from Tactic Pharma, LLC, resulting in a net decrease in his total beneficial ownership.

Monopar Therapeutics CEO Chandler Robinson reported the acquisition of 8,724 common shares through RSU vesting and the disposition of 2,558 shares for tax withholding.

Monopar Therapeutics' COO, Andrew Cittadine, reported an increase in direct common stock ownership following RSU vesting and tax-related share disposition.

Monopar Therapeutics reported an equity grant of 2,000 stock options to Patrice Rioux, its Acting Chief Medical Officer, with an exercise price of $65.3.

Monopar Therapeutics' Chief Financial Officer, Quan Anh Vu, reported a planned acquisition of 1,500 shares of common stock at $69.95 per share under a Rule 10b5-1 plan.

Monopar Therapeutics director Arthur J. Klausner reported the sale of 5,121 shares of common stock in pre-planned transactions.

Diane Hendricks, a Director and 10% owner of Monopar Therapeutics, reported an indirect disposition of 43,499 shares of common stock with no pecuniary interest.

Monopar Therapeutics Director Arthur J. Klausner reported acquiring 7,710 shares of common stock through a pro rata distribution.

Monopar Therapeutics' Chief Operating Officer, Andrew Cittadine, acquired stock options and restricted stock units on December 2, 2025, as part of an equity compensation plan.

Monopar Therapeutics director Christopher M. Starr was granted 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Monopar Therapeutics director Arthur J. Klausner was granted 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Monopar Therapeutics director Raymond Anderson was granted 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Monopar Therapeutics director Lavina Talukdar received a grant of 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Monopar Therapeutics Director Kim R Tsuchimoto was granted 2,924 stock options with an exercise price of $75.94.

Monopar Therapeutics' Chief Financial Officer, Quan Anh Vu, acquired 7,135 stock options and 9,826 restricted stock units on December 2, 2025.

Monopar Therapeutics CEO Chandler Robinson acquired 16,753 stock options and 49,133 restricted stock units as part of compensation.

Monopar Therapeutics' COO, Andrew Cittadine, acquired 4,327 common shares from RSU vesting and disposed of 1,896 shares for tax withholding on September 30, 2025.

Monopar Therapeutics CEO Chandler Robinson reported the vesting of restricted stock units and associated tax-related share dispositions, increasing direct common stock holdings.

Tactic Pharma LLC, a 10% owner, sold 550,229 shares of Monopar Therapeutics common stock for $63.6098 per share, reducing its beneficial ownership.

Monopar Therapeutics director Kim R. Tsuchimoto sold 8,904 shares of common stock for approximately $356,000 after exercising stock options at a nominal price.

Monopar Therapeutics Director Christopher M. Starr exercised stock options and subsequently sold 16,800 shares of common stock for approximately $672,000.

Monopar Therapeutics CEO and Director Chandler Robinson exercised stock options and subsequently sold 16,800 shares of common stock for approximately $40.00 per share.

Monopar Therapeutics CEO and Director Chandler Robinson reported the vesting of 13,344 restricted stock units and the subsequent disposition of 5,865 shares for tax withholding, alongside an indirect beneficial ownership of 822,255 shares.